Video

Dr. Agarwal on Remaining Challenges in mCSPC

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program, Huntsman Cancer Institute, discusses remaining challenges in metastatic castration-sensitive prostate cancer (mCSPC).

The shift toward utilizing novel hormonal therapies in the frontline setting for men with mCSPC ​has resulted in a dramatic improvement in overall survival, without hindering quality of life​, explains Agarwal. Some of these therapies include apalutamide (Erleada), enzalutamide (Xtandi), and abiraterone ​acetate (Zytiga), Agarwal says.

However, patients with mCSPC ​who progress on these therapies ​represent a challenging population to treat ​with additional therapy. As such, future research efforts should aim to identify new targets​, as well as therapies with novel mechanisms of action, ​to meet the need of these patients, says Agarwal. Additionally, patients with mCSPCshould be treated as early as possible, Agarwal concludes.

Related Videos
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS